Elevance Health, Inc. $ELV Stock: Sterling Capital Management LLC Grows Holdings

Sterling Capital Management LLC lifted its position in Elevance Health, Inc. (NYSE:ELV) by 3.7% during the third quarter, Holdings Channel reports. The institutional investor owned 54,969 shares of the company’s stock after buying an additional 1,959 shares during the quarter. Sterling Capital Management LLC’s holdings in Elevance Health were worth $21,373,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of ELV. BlackRock Inc. acquired a new position in Elevance Health during the second quarter worth about $7,344,424,000. State Street Corp raised its holdings in shares of Elevance Health by 1.3% in the 2nd quarter. State Street Corp now owns 10,426,610 shares of the company’s stock worth $4,032,283,000 after purchasing an additional 137,914 shares in the last quarter. Wellington Management Group LLP lifted its stake in Elevance Health by 12.0% during the second quarter. Wellington Management Group LLP now owns 9,213,513 shares of the company’s stock valued at $3,563,142,000 after purchasing an additional 984,976 shares during the last quarter. First Eagle Investment Management LLC boosted its holdings in Elevance Health by 1.4% during the second quarter. First Eagle Investment Management LLC now owns 4,188,196 shares of the company’s stock worth $1,619,701,000 after buying an additional 55,905 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in shares of Elevance Health during the 2nd quarter worth $1,246,349,000. Institutional investors own 89.24% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Weiss Ratings restated a “hold (c)” rating on shares of Elevance Health in a report on Thursday, August 13th. Wall Street Zen cut shares of Elevance Health from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Wells Fargo & Company dropped their price target on Elevance Health from $492.00 to $473.00 and set an “overweight” rating on the stock in a research report on Thursday, July 16th. Raymond James Financial set a $450.00 price target on Elevance Health in a report on Tuesday, July 7th. Finally, Robert W. Baird raised their price objective on shares of Elevance Health from $393.00 to $406.00 and gave the stock a “neutral” rating in a research note on Thursday. Fifteen research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $455.57.

Insider Buying and Selling at Elevance Health

In other Elevance Health news, CFO Mark Kaye sold 10,584 shares of the business’s stock in a transaction dated Thursday, October 22nd. The shares were sold at an average price of $440.13, for a total value of $4,658,335.92. Following the completion of the transaction, the chief financial officer directly owned 19,919 shares of the company’s stock, valued at approximately $8,766,949.47. The trade was a 34.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.34% of the company’s stock.

Elevance Health Stock Performance

ELV traded down $5.23 on Friday, hitting $440.05. 1,173,816 shares of the stock traded hands, compared to its average volume of 1,329,873. The business has a fifty day moving average price of $408.32 and a two-hundred day moving average price of $390.89. The company has a current ratio of 1.47, a quick ratio of 1.52 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $95.43 billion, a PE ratio of 18.77, a P/E/G ratio of 2.32 and a beta of 0.70. Elevance Health, Inc. has a 52 week low of $274.84 and a 52 week high of $450.69.

Elevance Health (NYSE:ELV) last issued its earnings results on Wednesday, October 21st. The company reported $6.99 earnings per share for the quarter, beating the consensus estimate of $4.71 by $2.28. Elevance Health had a net margin of 2.55% and a return on equity of 14.97%. The business had revenue of $50.44 billion for the quarter, compared to analyst estimates of $49.28 billion. During the same period in the previous year, the business earned $6.03 EPS. The firm’s revenue was up .7% on a year-over-year basis. On average, research analysts predict that Elevance Health, Inc. will post 27.09 EPS for the current fiscal year.

Elevance Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 18th. Stockholders of record on Friday, December 4th will be paid a $1.72 dividend. The ex-dividend date is Friday, December 4th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.6%. Elevance Health’s dividend payout ratio (DPR) is 29.34%.

Key Headlines Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Third-quarter adjusted earnings per share rose 15.9% and exceeded consensus, while revenue also topped expectations. Elevance raised its 2026 adjusted EPS outlook to at least $29, citing disciplined cost management and improved medical-cost trends. Elevance Health Q3 Results
• Positive Sentiment: Carelon’s expansion and clinical programs remain growth drivers; its cancer program reportedly reduced avoidable inpatient admissions by 15%. Management also highlighted actions intended to improve Medicaid profitability. ELV Q3 Deep Dive
• Positive Sentiment: TD Cowen raised its price target to $495 from $465 and maintained a Buy rating, indicating continued confidence in the earnings recovery. TD Cowen Rating
• Positive Sentiment: Elevance declared a quarterly dividend of $1.72 per share, supporting its shareholder-return profile. Elevance Health Dividend
• Neutral Sentiment: Elevance appointed Jeff Park as president of Carelon in a services leadership shift. The move may support execution, but its financial impact is not yet clear. Carelon Leadership Shift
• Neutral Sentiment: Morgan Stanley lifted its target to $449 from $404 but retained an Equal Weight rating, suggesting limited upside after the recent advance. Morgan Stanley Rating
• Negative Sentiment: Officer Mark B. Kaye disclosed an intent to sell 10,584 shares valued at approximately $4.66 million. While the sale may be routine, it can weigh on sentiment near a 52-week high. Officer Share Sale
• Negative Sentiment: Analysts continue to flag sustainability risks: nine-month operating gain declined, and Medicaid margins remain under pressure. Robert W. Baird kept a Neutral rating with a $406 target, below the current trading level. Elevance Health Earnings Analysis

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a diversified health benefits company that provides health insurance and related services in the United States. Its offerings serve employers, individuals and families, as well as members of government-sponsored programs, including Medicare and Medicaid. The company provides medical, pharmacy, behavioral health and other benefits through a range of health plans and specialty products.

Elevance Health operates its health benefits businesses through a portfolio that includes Blue Cross and Blue Shield-affiliated plans and other insurance offerings.